Home > Insider Trading > Filing (0001178913-14-001206)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1176309	Oramed Pharmaceuticals Inc.	ORMP	Pharmaceutical Preparations (2834)	980376008

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1409232	Miriam Kidron	2 Elza Street Jerusalem L3 93706	Chief Technology Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-04-01	137,300	$0.01	137,300	No	4	M	Direct
Common Stock	Disposition	2014-04-01	137,300	$12.03	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant (right to buy)	Disposition	2014-04-01	137,300	$0.00	137,300	$0.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
142,814	2012-08-08	2014-08-06	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.70 to $12.245, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.
The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.
The warrant was originally granted to the reporting person on August 14, 2007 and amended on August 8, 2012, resulting in the deemed cancellation of the "old" warrant and the grant of a replacement warrant.
The warrant was granted in recognition of the reporting person's contributions to the issuer in connection with the initial development of its current business.